AAPL333.68+12.02 (+3.74%) ▲|ABBV258.99+2.07 (+0.81%) ▲|ABT103.41+2.66 (+2.64%) ▲|ACN145.26+6.52 (+4.70%) ▲|ADBE222.64+10.47 (+4.93%) ▲|AMAT554.56-8.24 (-1.46%) ▼|AMD540.66+0.97 (+0.18%) ▲|AMGN376.31+4.81 (+1.29%) ▲|AMT167.64+2.99 (+1.81%) ▲|AMZN233.76+0.10 (+0.04%) ▲|AVGO386.30-6.17 (-1.57%) ▼|AXP323.50-17.34 (-5.09%) ▼|BA212.20+2.97 (+1.42%) ▲|BAC62.11+0.83 (+1.36%) ▲|BKNG178.30+5.47 (+3.17%) ▲|BLK1,051.03+13.87 (+1.34%) ▲|BMY62.31+0.80 (+1.29%) ▲|BNY159.71-0.41 (-0.25%) ▼|BRK-B495.31+4.46 (+0.91%) ▲|C132.64+0.76 (+0.57%) ▲|CAT900.65+6.11 (+0.68%) ▲|CL90.44+0.36 (+0.40%) ▲|CMCSA22.22+0.30 (+1.35%) ▲|COF203.00+3.04 (+1.52%) ▲|COP120.00-0.20 (-0.17%) ▼|COST931.57+5.51 (+0.59%) ▲|CRM162.54+5.61 (+3.57%) ▲|CSCO114.10+1.34 (+1.19%) ▲|CVS107.61+0.72 (+0.67%) ▲|CVX194.59+0.17 (+0.08%) ▲|DE621.33+11.31 (+1.85%) ▲|DHR191.66-0.84 (-0.44%) ▼|DIS95.60+2.77 (+2.98%) ▲|DUK129.78+0.52 (+0.40%) ▲|EMR149.15+4.25 (+2.93%) ▲|FDX317.24+1.62 (+0.51%) ▲|GD386.10+4.31 (+1.13%) ▲|GE357.12+8.12 (+2.33%) ▲|GEV1,025.39-5.80 (-0.56%) ▼|GILD130.26-0.60 (-0.46%) ▼|GM83.30+2.63 (+3.26%) ▲|GOOG319.53+1.19 (+0.37%) ▲|GOOGL319.73+2.04 (+0.64%) ▲|GS1,072.63-2.09 (-0.19%) ▼|HD330.54+5.83 (+1.80%) ▲|HON241.42-4.86 (-1.97%) ▼|IBM215.22+8.57 (+4.15%) ▲|INTC95.66-4.57 (-4.56%) ▼|INTU292.53+11.00 (+3.91%) ▲|ISRG339.93+7.91 (+2.38%) ▲|JNJ262.95+3.68 (+1.42%) ▲|JPM353.04+3.14 (+0.90%) ▲|KO81.85+0.68 (+0.83%) ▲|LIN508.74+2.42 (+0.48%) ▲|LLY1,200.92+15.05 (+1.27%) ▲|LMT580.05+11.46 (+2.02%) ▲|LOW206.26+4.34 (+2.15%) ▲|LRCX316.59-3.20 (-1.00%) ▼|MA535.04+4.75 (+0.90%) ▲|MCD265.54+2.74 (+1.04%) ▲|MDLZ60.12+0.07 (+0.12%) ▲|MDT83.06+1.05 (+1.28%) ▲|META603.60-2.50 (-0.41%) ▼|MMM172.05+2.46 (+1.45%) ▲|MO72.84+0.76 (+1.05%) ▲|MRK131.25+0.77 (+0.59%) ▲|MS215.61+0.43 (+0.20%) ▲|MSFT384.83+3.25 (+0.85%) ▲|MU944.25-45.97 (-4.64%) ▼|NEE89.57-0.22 (-0.25%) ▼|NFLX69.96+1.07 (+1.55%) ▲|NKE41.78+0.79 (+1.93%) ▲|NOW97.50+5.56 (+6.05%) ▲|NVDA210.84+2.08 (+1.00%) ▲|ORCL118.37-1.67 (-1.39%) ▼|PEP135.88+0.93 (+0.69%) ▲|PFE24.63+0.05 (+0.18%) ▲|PG147.04+1.15 (+0.79%) ▲|PLTR123.66+0.29 (+0.24%) ▲|PM193.35+2.23 (+1.17%) ▲|QCOM169.70-1.41 (-0.82%) ▼|RTX213.70+4.54 (+2.17%) ▲|SBUX104.37+1.16 (+1.12%) ▲|SCHW101.92+0.31 (+0.30%) ▲|SO96.87+0.27 (+0.28%) ▲|SPG228.93+3.73 (+1.66%) ▲|T23.75+0.79 (+3.42%) ▲|TMO560.20-12.12 (-2.12%) ▼|TMUS178.67+8.25 (+4.84%) ▲|TSLA310.90-8.80 (-2.75%) ▼|TXN280.23-4.76 (-1.67%) ▼|UBER69.55+0.64 (+0.93%) ▲|UNH421.57-1.99 (-0.47%) ▼|UNP308.30+3.97 (+1.30%) ▲|UPS114.80+0.70 (+0.61%) ▲|USB64.00+0.67 (+1.05%) ▲|V354.26+2.66 (+0.76%) ▲|VZ45.19+1.37 (+3.12%) ▲|WFC86.76+0.57 (+0.66%) ▲|WMT109.11+0.71 (+0.66%) ▲|XOM156.61-0.28 (-0.18%) ▼|AAPL333.68+12.02 (+3.74%) ▲|ABBV258.99+2.07 (+0.81%) ▲|ABT103.41+2.66 (+2.64%) ▲|ACN145.26+6.52 (+4.70%) ▲|ADBE222.64+10.47 (+4.93%) ▲|AMAT554.56-8.24 (-1.46%) ▼|AMD540.66+0.97 (+0.18%) ▲|AMGN376.31+4.81 (+1.29%) ▲|AMT167.64+2.99 (+1.81%) ▲|AMZN233.76+0.10 (+0.04%) ▲|AVGO386.30-6.17 (-1.57%) ▼|AXP323.50-17.34 (-5.09%) ▼|BA212.20+2.97 (+1.42%) ▲|BAC62.11+0.83 (+1.36%) ▲|BKNG178.30+5.47 (+3.17%) ▲|BLK1,051.03+13.87 (+1.34%) ▲|BMY62.31+0.80 (+1.29%) ▲|BNY159.71-0.41 (-0.25%) ▼|BRK-B495.31+4.46 (+0.91%) ▲|C132.64+0.76 (+0.57%) ▲|CAT900.65+6.11 (+0.68%) ▲|CL90.44+0.36 (+0.40%) ▲|CMCSA22.22+0.30 (+1.35%) ▲|COF203.00+3.04 (+1.52%) ▲|COP120.00-0.20 (-0.17%) ▼|COST931.57+5.51 (+0.59%) ▲|CRM162.54+5.61 (+3.57%) ▲|CSCO114.10+1.34 (+1.19%) ▲|CVS107.61+0.72 (+0.67%) ▲|CVX194.59+0.17 (+0.08%) ▲|DE621.33+11.31 (+1.85%) ▲|DHR191.66-0.84 (-0.44%) ▼|DIS95.60+2.77 (+2.98%) ▲|DUK129.78+0.52 (+0.40%) ▲|EMR149.15+4.25 (+2.93%) ▲|FDX317.24+1.62 (+0.51%) ▲|GD386.10+4.31 (+1.13%) ▲|GE357.12+8.12 (+2.33%) ▲|GEV1,025.39-5.80 (-0.56%) ▼|GILD130.26-0.60 (-0.46%) ▼|GM83.30+2.63 (+3.26%) ▲|GOOG319.53+1.19 (+0.37%) ▲|GOOGL319.73+2.04 (+0.64%) ▲|GS1,072.63-2.09 (-0.19%) ▼|HD330.54+5.83 (+1.80%) ▲|HON241.42-4.86 (-1.97%) ▼|IBM215.22+8.57 (+4.15%) ▲|INTC95.66-4.57 (-4.56%) ▼|INTU292.53+11.00 (+3.91%) ▲|ISRG339.93+7.91 (+2.38%) ▲|JNJ262.95+3.68 (+1.42%) ▲|JPM353.04+3.14 (+0.90%) ▲|KO81.85+0.68 (+0.83%) ▲|LIN508.74+2.42 (+0.48%) ▲|LLY1,200.92+15.05 (+1.27%) ▲|LMT580.05+11.46 (+2.02%) ▲|LOW206.26+4.34 (+2.15%) ▲|LRCX316.59-3.20 (-1.00%) ▼|MA535.04+4.75 (+0.90%) ▲|MCD265.54+2.74 (+1.04%) ▲|MDLZ60.12+0.07 (+0.12%) ▲|MDT83.06+1.05 (+1.28%) ▲|META603.60-2.50 (-0.41%) ▼|MMM172.05+2.46 (+1.45%) ▲|MO72.84+0.76 (+1.05%) ▲|MRK131.25+0.77 (+0.59%) ▲|MS215.61+0.43 (+0.20%) ▲|MSFT384.83+3.25 (+0.85%) ▲|MU944.25-45.97 (-4.64%) ▼|NEE89.57-0.22 (-0.25%) ▼|NFLX69.96+1.07 (+1.55%) ▲|NKE41.78+0.79 (+1.93%) ▲|NOW97.50+5.56 (+6.05%) ▲|NVDA210.84+2.08 (+1.00%) ▲|ORCL118.37-1.67 (-1.39%) ▼|PEP135.88+0.93 (+0.69%) ▲|PFE24.63+0.05 (+0.18%) ▲|PG147.04+1.15 (+0.79%) ▲|PLTR123.66+0.29 (+0.24%) ▲|PM193.35+2.23 (+1.17%) ▲|QCOM169.70-1.41 (-0.82%) ▼|RTX213.70+4.54 (+2.17%) ▲|SBUX104.37+1.16 (+1.12%) ▲|SCHW101.92+0.31 (+0.30%) ▲|SO96.87+0.27 (+0.28%) ▲|SPG228.93+3.73 (+1.66%) ▲|T23.75+0.79 (+3.42%) ▲|TMO560.20-12.12 (-2.12%) ▼|TMUS178.67+8.25 (+4.84%) ▲|TSLA310.90-8.80 (-2.75%) ▼|TXN280.23-4.76 (-1.67%) ▼|UBER69.55+0.64 (+0.93%) ▲|UNH421.57-1.99 (-0.47%) ▼|UNP308.30+3.97 (+1.30%) ▲|UPS114.80+0.70 (+0.61%) ▲|USB64.00+0.67 (+1.05%) ▲|V354.26+2.66 (+0.76%) ▲|VZ45.19+1.37 (+3.12%) ▲|WFC86.76+0.57 (+0.66%) ▲|WMT109.11+0.71 (+0.66%) ▲|XOM156.61-0.28 (-0.18%) ▼|
27.6 C
New York
Friday, July 24, 2026

Tag: pharmaceuticals

newssourceFORcompanyinformationcontent1releasesmarket

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /CNW/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.

Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

Cosmos Health has now repurchased a total of 4,838,000 shares for approximately $1.04 million.

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

Ji'an, Jiangxi, China, June 26, 2026 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ: UPC) (“Universe Pharmaceuticals” or the “Company”), a pharmaceutical producer and distributor in China, today announced that the Company has entered into a share purchase agreement to acquire 100% of the issued shares of Best Praise International Limited (“Best Praise”), a company that holds five patents in China with potential applications in pharmaceutical development, for a total purchase price of US$10,751,000, payable in the form of 4,376,552 Class A ordinary shares of the Company.

Scientology Network Presents Special Marathon for International Day Against Drug Abuse

LOS ANGELES, June 26, 2026 /PRNewswire/ -- As the world marks the UN's International Day Against Drug Abuse and Illicit Trafficking on June 26,...

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar’s Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

Alitheon FeaturePrint® Named “Overall Authentication Solution of the Year” in 2026 AI Breakthrough Awards Program

Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global Innovation 
Ninth Annual Program Honors the AI Innovators Shaping the Next Era of Global Innovation

Lupin Receives Tentative Approval from U.S. FDA for Enzalutamide Tablets

MUMBAI, India and NAPLES, Fla., June 26, 2026 /CNW/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN)...

Idorsia confirms successful closing of Pharmakon loan agreement and full repayment of New Money Facility

Allschwil, Switzerland – June 26, 2026
Idorsia Ltd (SIX: IDIA), a commercial-stage biopharmaceutical company with a portfolio of first- or best-in-class assets, today confirmed the successful closing of its previously announced senior secured term loan agreement of up to CHF 250 million with investment funds managed by Pharmakon Advisors, LP.

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

Rare Neurological Disease Treatment Market to Reach USD 43.7 Billion by 2036 as Orphan Drug Approvals and Genetic Diagnostics Expand Specialist Care | Future...

NEWARK, Del., June 25, 2026 /PRNewswire/ -- According to a recent study by Future Market Insights (FMI), the global Rare Neurological Disease Treatment Market...

[Latest] Global Therapeutic Apheresis Market Size/Share Worth USD 8.94 Billion by 2035 at a 7.9% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast,...

[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at approximately USD 3.84 Billion in 2025 and is expected to reach USD 4.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Terumo BCT Inc., Fresenius Kabi AG, Haemonetics Corporation, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec GmbH, Nikkiso Co. Ltd., Kaneka Corporation, Mallinckrodt Pharmaceuticals (Uvadex/ECP), Photomedex Inc., Macopharma SAS and others. 
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Therapeutic Apheresis Market size & share revenue was valued at approximately USD 3.84 Billion in 2025 and is expected to reach USD 4.18 Billion in 2026 and is expected to reach around USD 8.94 Billion by 2035, at a CAGR of 7.9% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Terumo BCT Inc., Fresenius Kabi AG, Haemonetics Corporation, B. Braun Melsungen AG, Asahi Kasei Medical Co. Ltd., Miltenyi Biotec GmbH, Nikkiso Co. Ltd., Kaneka Corporation, Mallinckrodt Pharmaceuticals (Uvadex/ECP), Photomedex Inc., Macopharma SAS and others.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPharmaceuticals

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers